Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 5/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | HTR3A | P46098 | 2/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285344 | 1.00 | PTGDR2 (0.35) | PTGDR2CNR1CNR2NPC1HTR6 | |
| SCHEMBL6281786 | 0.87 | HTR6 (0.43) | CNR1CNR2NPC1HTR6HTR3A | |
| SCHEMBL6281788 | 0.87 | HTR6 (0.43) | CNR1CNR2NPC1HTR6HTR3A | |
| SCHEMBL6282010 | 0.86 | PTGDR2 (0.37) | PTGDR2CNR1CNR2HTR6ICMT | |
| SCHEMBL6282008 | 0.86 | PTGDR2 (0.37) | PTGDR2CNR1CNR2HTR6ICMT | |
| SCHEMBL6282103 | 0.86 | HTR3A (0.41) | HTR3A | |
| SCHEMBL6282097 | 0.86 | HTR3A (0.41) | HTR3A | |
| SCHEMBL6282805 | 0.85 | CNR2 (0.37) | PTGDR2CNR1CNR2HTR6ICMT | |
| SCHEMBL6282800 | 0.85 | CNR2 (0.37) | PTGDR2CNR1CNR2HTR6ICMT | |
| SCHEMBL6282816 | 0.84 | SLC6A9 (0.34) | CNR1CNR2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906095-B2 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2A | PTGDR2 208/4885CNR1 33/4885CNR2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.